Cargando…
Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review.
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare type of leukemia in children, Although BPDCN is a chemo-sensitive tumor, the relapse rate is very high. Tagraxofusp, which is a CD123-directed cytotoxin has been used as a targeted therapy and has shown promising results in patients...
Autores principales: | Abla, Dima, Abboud, Miguel R., Noun, Dolly, Tarek, Nidale, Pemmaraju, Naveen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027275/ https://www.ncbi.nlm.nih.gov/pubmed/35462725 http://dx.doi.org/10.1016/j.lrr.2022.100313 |
Ejemplares similares
-
Allogeneic Hematopoietic Cell Transplantation for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
por: Bashir, Qaiser, et al.
Publicado: (2022) -
Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN)
por: Beird, Hannah C., et al.
Publicado: (2019) -
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in an Elderly Female: A Rare Case
por: Al-Alwan, Ahmad, et al.
Publicado: (2023) -
Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
por: Abdallah, Mostafa, et al.
Publicado: (2023) -
Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data
por: Beziat, Guillaume, et al.
Publicado: (2020)